A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Completed · Phase 3

Conditions studied: Multiple Myeloma

In brief

This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.

Key facts

Study ID

NCT00546780

Run by

Bristol-Myers Squibb

People needed

31

Starts

2008-02-01

Expected to finish

2010-03-01

Last updated by the study team

2011-06-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Good Performance Status
• Documented evidence of multiple myeloma
• Documented progression of disease after initial response to one line of therapy
• Measurable disease (serum M-protein >.5g/dl or > 200 mg urinary M protein excretion)

You may not qualify if…

• Prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor
• Known active infections of HAV, HBV, HCV, or HIV
• Administration of chemotherapy, radiation therapy, or immune therapy within 21 days prior to randomization.
• Acute diffuse infiltrate pulmonary disease or pericardial dise

Where it is running

• Comprehensive Blood And Cancer Center — Bakersfield, California, United States
• Moores Ucsd Cancer Center — La Jolla, California, United States
• University Of California Medical Center — San Francisco, California, United States
• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• University Of Iowa Hospitals And Clinics — Iowa City, Iowa, United States
• University Of Kansas Medical Center — Westwood, Kansas, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Henry Ford Health System Irb — Detroit, Michigan, United States
• Capitol Comprehensive Cancer Care Center — Jefferson City, Missouri, United States
• Columbia University Medical Center (Cumc) — New York, New York, United States
• Wake Forest Univ Health Sciences — Winston-Salem, North Carolina, United States
• Kaiser Permanente Oncology/Hematology — Portland, Oregon, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Tennessee Cancer Specialists — Knoxville, Tennessee, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Baylor University Medical Center — Dallas, Texas, United States
• University Of Virginia Health System — Charlottesville, Virginia, United States
• Medical College Of Wisconsin — Milwaukee, Wisconsin, United States
• Local Institution — Edmonton, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.